KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Current Assets (2016 - 2025)

Historic Current Assets for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $24.1 billion.

  • Gsk's Current Assets rose 709.41% to $24.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 billion, marking a year-over-year increase of 709.41%. This contributed to the annual value of $21.7 billion for FY2024, which is 630.88% down from last year.
  • Per Gsk's latest filing, its Current Assets stood at $24.1 billion for Q3 2025, which was up 709.41% from $23.6 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Current Assets ranged from a high of $68.2 billion in Q2 2022 and a low of $20.5 billion during Q1 2022
  • In the last 5 years, Gsk's Current Assets had a median value of $24.0 billion in 2023 and averaged $26.0 billion.
  • As far as peak fluctuations go, Gsk's Current Assets surged by 17793.39% in 2022, and later tumbled by 6452.01% in 2023.
  • Over the past 5 years, Gsk's Current Assets (Quarter) stood at $25.2 billion in 2021, then decreased by 3.23% to $24.4 billion in 2022, then decreased by 5.01% to $23.1 billion in 2023, then fell by 5.72% to $21.8 billion in 2024, then rose by 10.33% to $24.1 billion in 2025.
  • Its last three reported values are $24.1 billion in Q3 2025, $23.6 billion for Q2 2025, and $22.8 billion during Q1 2025.